论文部分内容阅读
[目的]分析辅助治疗对中晚期食管癌的临床价值。[方法]230例中晚期食管癌(T2~4NXMO)患者,按照治疗方法分成4组,NRT组予术前放疗,NCRT组予术前放化疗,PRT组予术后放疗,PCRT组予术后放化疗,分析4组复发率、5年生存率。[结果]NRT、NCRT、PRT、PCRT组1年局部复发率分别为72.8%、30.7%、80.1%、35.6%,差异有显著性(χ2=4.159,P=0.000);5年生存率分别为8.82%、33.33%、14.28%和19.18%,差异有显著性(χ2=13.812,P=0.003)。[结论]术前放化疗治疗中晚期食管癌可降低局部复发率,并提高远期生存率。
[Objective] To analyze the clinical value of adjuvant therapy for advanced esophageal cancer. [Methods] 230 patients with advanced esophageal cancer (T2 ~ 4NXMO) were divided into 4 groups according to the treatment method. NRT group received preoperative radiotherapy, NCRT group received preoperative chemoradiotherapy, PRT group received postoperative radiotherapy, and PCRT group Radiotherapy and chemotherapy, analysis of 4 groups recurrence rate, 5-year survival rate. [Results] The local recurrence rates at 1 year in NRT, NCRT, PRT and PCRT groups were 72.8%, 30.7%, 80.1% and 35.6%, respectively (χ2 = 4.159, P = 0.000) 8.82%, 33.33%, 14.28% and 19.18%, respectively (χ2 = 13.812, P = 0.003). [Conclusion] Preoperative chemoradiotherapy for advanced esophageal cancer can reduce the local recurrence rate and improve the long-term survival rate.